Edwin Charlebois, PhD, MPH

Professor, Department of Medicine at the University of California, San Francisco
Co-Director of the Methods/Biostatistics Core within the UCSF Center for AIDS Prevention Studies (CAPS)


E-mail Address:  Edwin.Charlebois@ucsf.edu

 

Edwin Charlebois

Research Interests:
HIV, epidemiology, biostatistics, prevention, policy, clinical trials, medication adherence, Tuberculosis, Malaria, co-infection, operations research, stigma, antibiotic resistance, Methicillin-Resistant Staph. aureus (MRSA)

 

Education and Training:
University of California San Francisco, CAPS, Faculty, (AIDS/HIV Research), 2005-Present


University of California San Francisco, Center for AIDS Prevention Studies, Fellowship, (AIDS/HIV Research), 1995-1997


University of California Berkeley, PhD (Epidemiology), 1994-1998


University of California Berkeley, MPH (Epidemiolgy – Biostatistics), 1988-1990


University of California Berkeley, BA (Genetics), 1979-1984

 

Publications:

1. Charlebois ED, Ruel TD, Gasasira AF, Achan J, Kateera F, Akello C, Cao H, Dorsey G, Rosenthal PJ, Ssewanyana I, Kamya MR, Havlir DV. Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Nov;55(3):330-5. PMCID: PMC3025136


2. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011 Apr 15;52(8):1046-9. PMCID: PMC3070031


3. Charlebois ED, Havlir DV. "A bird in the hand...": a commentary on the test and treat approach for HIV. Archives of internal medicine. 2010 Aug 9;170(15):1354-6. PMID: 20696961


4. Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, Dorsey G, Rosenthal PJ, Havlir DV, Wong JK, Achan J. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011 Jan;56(1):44-50. PMCID: PMC3078046


5. Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, Rosenthal PJ, Dorsey G, Achan J, Akello C, Kamya MR, Wong JK. Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis. 2012 Apr;54(7):1001-9. Epub 2012 Feb 4. PMCID: PMC3297647


6. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, Achan J, Charlebois ED, Feeney ME. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis. 2011 Sep;53(6):592-9. Epub 2011 Aug 12. PMCID: PMC3160805


7. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):424-9. PMID: 19506482


8. Bebell LM, Pilcher CD, Dorsey G, Havlir D, Kamya MR, Busch MP, Dunn Williams J, Nugent CT, Bentsen C, Rosenthal PJ, Charlebois ED. Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS. 2010 Jul 31;24(12):1945-52. PMCID: PMC2909782


9. Morin SF, Kelly JA, Charlebois ED, Remien RH, Rotheram-Borus MJ, Cleary PD. Responding to the National HIV/AIDS Strategy-setting the research agenda. Journal of acquired immune deficiency syndromes. 2011 Jul 1;57(3):175-80. PMCID: PMC3159729


10. Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, Mupere E, et al. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4 T-cell counts of >/= 350 cells/muL. The Journal of infectious diseases. 2011 Sep 15;204(6):884-92. PMCID: PMC3156928


11. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (London, England). 2003 Sep 5;17(13):1925-32.


12. Johnson MO, Catz SL, Remien RH, Rotheram-Borus MJ, Morin SF, Charlebois E, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS patient care and STDs. 2003 Dec;17(12):645-56.


13. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. The Journal of infectious diseases. 2004 Jul 1;190(1):162-5.


14. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV clinical trials. 2004 Mar-Apr;5(2):74-9.


15. Liechty CA, Alexander CS, Harrigan PR, Guzman JD, Charlebois ED, Moss AR, et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS (London, England). 2004 Jan 2;18(1):127-9.